Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Lung Diseases 1Liposarcoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Squamous Cell 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

Etoposide 79Carboplatin 67Cisplatin 58durvalumab 29Irinotecan 29Radiotherapy 27atezolizumab 23Topotecan 21anlotinib 19Nivolumab 15Drug Therapy 15Radiosurgery 14Gemcitabine 13apatinib 12Paclitaxel 12toripalimab 10Platinum 10Docetaxel 10tislelizumab 9Temozolomide 9PM 01183 8pembrolizumab 7olaparib 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Bevacizumab 7Albumin-Bound Paclitaxel 7irinotecan sucrosofate 6Counseling 6sintilimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Carcinoma × sitravatinib × Clear all
NCT05228496 2023-09-26

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Zhejiang Cancer Hospital

Phase 2 Unknown
21 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡